Market Summary
USD56.52-0.58
Delayedas of 21 Sep 2023, 12:16 pm-1.02%
LIVN Alerts
LIVN Stock Price
LIVN RSI Chart
LIVN Valuation
LIVN Price/Sales (Trailing)
LIVN Profitability
LIVN Fundamentals
LIVN Revenue
LIVN Earnings
Price Action
52 Week Range
40.2659.86
(Low)(High)
Last 7 days
0.2%
Last 30 days
3.8%
Last 90 days
13.5%
Trailing 12 Months
7.7%
LIVN Financial Health
LIVN Investor Care
Historical Charts for Stock Metrics
Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
Get all data in R, Python etc through our Historical Stock Data APIs
Latest Insider Trading transactions for LIVN
Filter Transactions| Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
|---|---|---|---|---|---|---|
2023-09-15 | Story Brooke | acquired | - | - | 1,725 | - |
2023-09-15 | Hebbelinck Trui | sold (taxes) | -11,757 | 56.8 | -207 | chief human resources officer |
2023-09-15 | Hebbelinck Trui | acquired | - | - | 440 | chief human resources officer |
2023-09-15 | Story Brooke | sold (taxes) | -19,941 | 57.8 | -345 | - |
2023-06-15 | Shvartsburg Alex | sold (taxes) | -35,912 | 48.4 | -742 | cfo |
2023-06-15 | O'Kane Sharon | sold (taxes) | -47,383 | 48.4 | -979 | - |
2023-06-15 | Saia Andrea Lynn | sold (taxes) | -21,538 | 48.4 | -445 | - |
2023-06-15 | KOZY WILLIAM A | acquired | - | - | 3,284 | - |
2023-06-15 | SCHERMERHORN TODD C | acquired | - | - | 2,082 | - |
2023-06-15 | O'Kane Sharon | acquired | - | - | 2,082 | - |
Which funds bought or sold LIVN recently?
View All Details| Datesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
|---|---|---|---|---|---|---|
2023-09-05 | Delos Wealth Advisors, LLC | unchanged | - | 235 | 1,543 | -% |
2023-08-22 | VIRGINIA RETIREMENT SYSTEMS ET AL | reduced | -3.19 | 175,083 | 1,404,040 | 0.01% |
2023-08-21 | CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | reduced | -2.7 | 432,823 | 3,352,460 | -% |
2023-08-21 | TEACHERS RETIREMENT SYSTEM OF THE STATE OF KENTUCKY | added | 10.25 | 113,000 | 488,000 | -% |
2023-08-21 | OSAIC HOLDINGS, INC. | reduced | -3.74 | 21,401 | 178,585 | -% |
2023-08-16 | Thomas J. Herzfeld Advisors, Inc. | unchanged | - | 65,391 | 428,412 | 0.17% |
2023-08-16 | Nuveen Asset Management, LLC | added | 153 | 14,558,600 | 21,879,600 | 0.01% |
2023-08-15 | Belpointe Asset Management LLC | sold off | -100 | -1,330 | - | -% |
2023-08-15 | ALLIANCEBERNSTEIN L.P. | added | 142 | 74,536,500 | 114,450,000 | 0.05% |
2023-08-15 | CAPTRUST FINANCIAL ADVISORS | new | - | 1,245,070 | 1,245,070 | -% |
Latest Funds Activity
Calls
Puts
Net Call Options
No. of Funds
LIVN Alerts
Schedule 13G FIlings of LivaNova
| Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
|---|---|---|---|---|---|
| May 09, 2023 | primecap management co/ca/ | 10.07% | 5,394,100 | SC 13G/A | |
| Feb 14, 2023 | harris associates l p | 3.8% | 2,008,159 | SC 13G/A | |
| Feb 09, 2023 | primecap management co/ca/ | 8.58% | 4,594,917 | SC 13G/A | |
| Jan 26, 2023 | blackrock inc. | 12.8% | 6,834,335 | SC 13G/A | |
| Jan 20, 2023 | blackrock inc. | 12.8% | 6,834,335 | SC 13G/A | |
| Feb 11, 2022 | harris associates l p | 7.2% | 3,823,266 | SC 13G/A | |
| Feb 10, 2022 | primecap management co/ca/ | 8.3% | 4,415,445 | SC 13G/A | |
| Jan 27, 2022 | blackrock inc. | 11.9% | 6,349,305 | SC 13G/A | |
| Jan 26, 2022 | blackrock inc. | 11.9% | 6,349,305 | SC 13G/A | |
| Feb 16, 2021 | price t rowe associates inc /md/ | 0.0% | 29,850 | SC 13G/A |
Recent SEC filings of LivaNova
View All Filings| Date Filed | Form Type | Document | |
|---|---|---|---|
| Sep 19, 2023 | 4 | Insider Trading | |
| Sep 19, 2023 | 4 | Insider Trading | |
| Jul 26, 2023 | 10-Q | Quarterly Report | |
| Jul 26, 2023 | 8-K | Current Report | |
| Jul 26, 2023 | IRANNOTICE | IRANNOTICE | |
| Jul 26, 2023 | S-8 | Employee Benefits Plan | |
| Jun 23, 2023 | 144 | Notice of Insider Sale Intent | |
| Jun 20, 2023 | 4 | Insider Trading | |
| Jun 20, 2023 | 144 | Notice of Insider Sale Intent | |
| Jun 20, 2023 | 4 | Insider Trading |
Peers (Alternatives to LivaNova)
View All Peers In Detail| Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
|---|---|---|---|---|---|---|---|---|
| LARGE-CAP | ||||||||
MDT | 108.4B | 31.6B | -0.16% | -7.89% | 29.89 | 3.44 | 1.57% | -30.40% |
ISRG | 102.6B | 6.7B | 1.85% | 46.31% | 71.98 | 15.39 | 11.75% | -0.66% |
EW | 43.7B | 5.7B | -5.74% | -17.48% | 31.48 | 7.73 | 5.64% | -4.53% |
ALGN | 23.7B | 3.7B | -9.66% | 33.28% | 75.41 | 6.34 | -6.33% | -49.26% |
HOLX | 17.6B | 4.0B | -5.02% | 10.52% | 36.44 | 4.37 | -22.73% | -67.98% |
| MID-CAP | ||||||||
PEN | 10.1B | 937.8M | 5.52% | 36.72% | 345.25 | 10.72 | 16.30% | 250.21% |
NVST | 4.6B | 2.6B | -14.78% | -16.57% | 21.31 | 1.79 | 1.78% | -15.77% |
CNMD | 3.3B | 1.1B | -0.07% | 19.99% | 36.85 | 2.86 | 9.28% | 177.49% |
LIVN | 3.1B | 1.1B | 3.78% | 7.70% | -31.64 | 2.83 | 6.60% | -233.50% |
TMDX | 1.9B | 151.1M | -11.99% | 20.86% | -105.48 | 12.39 | 193.70% | 62.80% |
| SMALL-CAP | ||||||||
ESTA | 1.3B | 177.1M | -10.61% | -16.28% | -20.84 | 7.16 | 23.02% | 15.37% |
AVNS | 952.1M | 780.7M | -7.00% | -11.88% | -26.45 | 1.22 | 4.68% | -510.17% |
BLFS | 551.7M | 162.2M | 16.09% | -48.52% | -6.56 | 3.4 | 9.71% | 12.37% |
INGN | 120.6M | 349.3M | -19.00% | -79.53% | -1.25 | 0.35 | -1.13% | -239.54% |
SDC | 54.3M | 414.9M | -23.20% | -60.93% | -0.66 | 0.13 | -23.37% | 16.91% |
LivaNova News
Returns for LIVN
Cumulative Returns on LIVN
-1.0%
7-Year Cumulative Returns
-14.1%
5-Year Cumulative Returns
8.5%
3-Year Cumulative Returns
Risks for LIVN
What is the probability of a big loss on LIVN?
87.7%
Probability that LivaNova stock will be more than 20% underwater in next one year
69.2%
Probability that LivaNova stock will be more than 30% underwater in next one year.
44.6%
Probability that LivaNova stock will be more than 40% underwater in next one year.
*Calculated based on probability distribution of losses observed in actual data in the last 5 years.
How does LIVN drawdown profile look like?
Y-axis is the maximum loss one would have experienced if LivaNova was unfortunately bought at previous high price.
Drawdowns
Financials for LivaNova
Income Statement (Last 12 Months)
| Income Statement (Last 12 Months) | ||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Revenue | 3.8% | 1,084,779,000 | 1,045,048,000 | 1,021,805,000 | 1,016,995,000 | 1,017,605,000 | 1,027,937,000 | 1,035,365,000 | 1,034,856,000 | 1,021,724,000 | 939,447,000 | 934,241,000 | 952,276,000 | 980,803,000 | 1,075,766,000 | 1,084,170,000 | 1,093,563,000 | 1,097,035,000 | 1,107,364,000 | 1,106,961,000 | 1,088,334,000 | 1,067,505,000 |
| Gross Profit | 2.9% | 733,715,000 | 712,868,000 | 707,228,000 | 725,354,000 | 723,100,000 | 711,029,000 | 705,994,000 | 671,246,000 | 650,173,000 | 592,864,000 | 594,763,000 | 570,490,667 | 560,554,000 | 661,228,000 | 723,805,000 | - | - | - | - | 702,465,000 | 689,976,000 |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 655,905,000 | 607,637,000 |
| S&GA Expenses | 2.0% | 484,237,000 | 474,847,000 | 469,243,000 | 474,070,000 | 468,482,000 | 474,748,000 | 471,904,000 | 462,321,000 | 457,315,000 | 437,310,000 | 446,561,000 | 479,490,000 | 498,469,000 | 522,939,000 | 528,466,000 | 498,163,000 | 490,284,000 | 486,510,000 | 464,967,000 | 444,031,000 | 426,096,000 |
| R&D Expenses | 10.2% | 181,768,000 | 164,873,000 | 155,805,000 | 154,971,000 | 161,379,000 | 179,707,000 | 183,414,000 | 183,795,000 | 189,030,000 | 161,625,000 | 152,902,000 | 131,248,000 | 129,784,000 | 139,176,000 | 146,849,000 | 161,587,000 | 158,100,000 | 157,771,000 | 145,948,000 | 140,778,000 | 121,264,000 |
| EBITDA | -100.0% | - | 5,607,000 | -4,519,000 | -19,966,000 | 39,895,000 | -27,364,000 | -49,785,000 | -332,329,000 | -305,241,000 | -218,586,000 | -208,878,000 | -72,414,000 | -42,134,000 | -57,688,000 | -76,331,000 | - | - | - | - | - | - |
| EBITDA Margin | -100.0% | - | 0.01 | 0.00 | -0.02 | 0.04 | -0.03 | -0.05 | -0.32 | -0.30 | -0.23 | -0.22 | -0.08 | -0.04 | -0.05 | -0.07 | - | - | - | - | - | - |
| Interest Expenses | 0.8% | 54,268,000 | 53,847,000 | 48,250,000 | 41,234,000 | 39,928,000 | 42,055,000 | 50,151,000 | 59,406,000 | 62,724,000 | 51,924,000 | 40,837,000 | 29,838,000 | 19,939,000 | 18,278,000 | 15,091,000 | 12,565,000 | 10,424,000 | 9,376,000 | 9,825,000 | 10,233,000 | 9,021,000 |
| Earnings Before Taxes | -19.3% | -84,664,000 | -70,943,000 | -75,142,000 | -83,836,000 | -19,287,000 | -90,826,000 | -124,472,000 | -423,809,000 | -400,966,000 | -370,092,000 | -348,022,000 | -199,208,000 | -159,029,000 | -172,922,000 | -188,378,000 | -314,909,000 | -345,307,000 | -290,987,000 | -247,447,000 | 39,800,000 | 78,060,000 |
| EBT Margin | 100.0% | - | -0.07 | -0.07 | -0.08 | -0.02 | -0.09 | -0.12 | -0.40 | -0.39 | -0.39 | -0.37 | -0.21 | -0.16 | -0.16 | -0.17 | - | - | - | - | - | - |
| Net Income | -18.7% | -97,158,000 | -81,869,000 | -86,246,000 | -93,034,000 | -29,133,000 | -102,064,000 | -135,818,000 | -411,741,000 | -383,112,000 | -416,040,000 | -348,819,000 | -210,999,000 | -164,067,000 | -103,867,000 | -155,176,000 | -222,507,000 | -261,802,000 | -217,521,000 | -189,399,000 | -90,526,000 | -55,519,000 |
| Net Income Margin | 100.0% | - | -0.08 | -0.08 | -0.09 | -0.03 | -0.10 | -0.13 | -0.40 | -0.37 | -0.44 | -0.37 | -0.22 | -0.16 | -0.10 | -0.14 | - | - | - | - | - | - |
| Free Cashflow | -100.0% | - | 35,868,000 | 43,404,000 | 59,730,000 | 50,815,000 | 86,414,000 | 77,066,000 | 81,577,000 | 59,062,000 | 11,456,000 | -114,446,000 | -149,876,000 | -230,635,000 | -226,708,000 | -115,833,000 | - | - | - | - | - | - |
Balance Sheet(In Millions)
| Balance Sheet | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Assets | 2.0% | 2,342 | 2,295 | 2,295 | 2,213 | 2,336 | 2,417 | 2,201 | 2,203 | 2,397 | 2,369 | 2,400 | 2,522 | 2,503 | 2,454 | 2,412 | 2,510 | 2,622 | 2,600 | 2,550 | 2,611 | 2,597 |
| Current Assets | 4.3% | 942 | 903 | 886 | 851 | 772 | 810 | 679 | 646 | 809 | 691 | 708 | 673 | 672 | 617 | 549 | 547 | 568 | 541 | 533 | 573 | 555 |
| Cash Equivalents | 4.0% | 223 | 214 | 214 | 231 | 407 | 442 | 208 | 182 | 329 | 253 | 253 | 228 | 233 | 126 | 61.00 | 75.00 | 45.00 | 51.00 | 47.00 | 80.00 | 47.00 |
| Inventory | 9.8% | 156 | 142 | 129 | 122 | 119 | 115 | 106 | 124 | 127 | 125 | 115 | 178 | 177 | 170 | 164 | 168 | 169 | 161 | 154 | 153 | 158 |
| Net PPE | 0.3% | 150 | 149 | 147 | 139 | 143 | 148 | 150 | 153 | 157 | 158 | 164 | 191 | 186 | 184 | 181 | 180 | 185 | 186 | 191 | 188 | 186 |
| Goodwill | 0.6% | 779 | 774 | 769 | 742 | 898 | 897 | 900 | 905 | 918 | 910 | 922 | 918 | 902 | 889 | 916 | 946 | 962 | 952 | 957 | 969 | 966 |
| Liabilities | 3.1% | 1,101 | 1,068 | 1,087 | 1,066 | 1,054 | 1,125 | 906 | 891 | 1,356 | 1,303 | 1,291 | 1,171 | 1,169 | 1,062 | 1,028 | 1,015 | 1,138 | 1,113 | 1,046 | 826 | 814 |
| Current Liabilities | -8.8% | 288 | 316 | 297 | 288 | 264 | 308 | 697 | 658 | 702 | 295 | 309 | 282 | 268 | 530 | 513 | 469 | 596 | 622 | 497 | 347 | 368 |
| LT Debt, Non Current | 9.2% | 568 | 520 | 518 | 518 | 460 | 456 | 10.00 | 11.00 | 431 | 646 | 642 | 637 | 639 | 316 | 260 | 273 | 174 | 142 | 140 | 108 | 50.00 |
| Shareholder's Equity | 1.1% | 1,241 | 1,227 | 1,208 | 1,147 | 1,282 | 1,292 | 1,295 | 1,299 | 1,029 | 1,055 | 1,109 | 1,351 | 1,333 | 1,393 | 1,378 | 1,495 | 1,483 | 1,487 | 1,500 | 1,785 | 1,783 |
| Retained Earnings | 0.1% | -975 | -976 | -984 | -985 | -878 | -894 | -897 | -879 | -837 | -782 | -761 | -472 | -457 | -369 | -406 | -263 | -295 | -266 | -251 | -40.93 | -33.76 |
| Additional Paid-In Capital | 0.3% | 2,169 | 2,163 | 2,158 | 2,144 | 2,133 | 2,121 | 2,118 | 2,107 | 1,779 | 1,770 | 1,768 | 1,758 | 1,751 | 1,740 | 1,735 | 1,725 | 1,717 | 1,707 | 1,705 | 1,751 | 1,744 |
| Shares Outstanding | 0.1% | 54.00 | 54.00 | 54.00 | 54.00 | 54.00 | 53.00 | 53.00 | 52.00 | 49.00 | 49.00 | 49.00 | 49.00 | 49.00 | 48.00 | 48.00 | 48.00 | 48.00 | 48.00 | 48.00 | 49.00 | 48.00 |
Cashflow (Last 12 Months)(In Millions)
| Cashflow (Last 12 Months) | (In Millions) | |||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Description | (%) Q/Q | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 | 2018Q4 | 2018Q3 | 2018Q2 |
| Cashflow From Operations | -11.9% | 57.00 | 65.00 | 70.00 | 85.00 | 73.00 | 109 | 103 | 106 | 91.00 | 46.00 | -79.42 | -113 | -198 | -199 | -91.14 | -73.12 | 55.00 | 102 | 120 | 117 | 108 |
| Share Based Compensation | -12.8% | 39.00 | 45.00 | 45.00 | 42.00 | 43.00 | 41.00 | 41.00 | 39.00 | 36.00 | 36.00 | 35.00 | 35.00 | 36.00 | 35.00 | 33.00 | 30.00 | 28.00 | 27.00 | 27.00 | 26.00 | 25.00 |
| Cashflow From Investing | 21.4% | -34.92 | -44.42 | -38.41 | -31.09 | -31.44 | 41.00 | 37.00 | 32.00 | 28.00 | -40.62 | -41.84 | -44.11 | -41.50 | -46.73 | -41.29 | -43.67 | -49.82 | -42.84 | -120 | -118 | -118 |
| Cashflow From Financing | 70.5% | 102 | 60.00 | 280 | 278 | 41.00 | 42.00 | -181 | -183 | -23.03 | 119 | 311 | 309 | 429 | 322 | 147 | 114 | -6.22 | -66.81 | -42.35 | 18.00 | 16.00 |
| Buy Backs | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 50.00 | - | - |
LIVN Income Statement
2023-06-30Condensed Consolidated Statements of Income - USD ($) shares in Thousands, $ in Thousands | 3 Months Ended | 6 Months Ended | ||
|---|---|---|---|---|
Jun. 30, 2023 | Jun. 30, 2022 | Jun. 30, 2023 | Jun. 30, 2022 | |
| Income Statement [Abstract] | ||||
| Net revenue | $ 293,882 | $ 254,151 | $ 557,300 | $ 494,326 |
| Cost of sales | 88,685 | 69,801 | 178,020 | 141,533 |
| Gross profit | 205,197 | 184,350 | 379,280 | 352,793 |
| Operating expenses: | ||||
| Selling, general and administrative | 125,872 | 116,482 | 250,001 | 235,007 |
| Research and development | 51,124 | 34,229 | 101,110 | 75,147 |
| Other operating expense | 10,825 | 1,883 | 13,135 | 1,378 |
| Operating income | 17,376 | 31,756 | 15,034 | 41,261 |
| Interest expense | (14,809) | (14,388) | (28,246) | (22,228) |
| Foreign exchange and other income/(expense) | 2,713 | 1,633 | 28,260 | 5,537 |
| Income before tax | 5,280 | 19,001 | 15,048 | 24,570 |
| Income tax expense | 4,097 | 2,515 | 6,468 | 5,052 |
| Losses from equity method investments | (28) | (42) | (55) | (81) |
| Net income | $ 1,155 | $ 16,444 | $ 8,525 | $ 19,437 |
| Basic income per share (in dollars per share) | $ 0.02 | $ 0.31 | $ 0.16 | $ 0.36 |
| Diluted income per share (in dollars per share) | $ 0.02 | $ 0.30 | $ 0.16 | $ 0.36 |
| Shares used in computing basic income per share (in shares) | 53,803 | 53,506 | 53,713 | 53,420 |
| Shares used in computing diluted income per share (in shares) | 53,977 | 54,080 | 53,942 | 54,144 |
LIVN Balance Sheet
2023-06-30Condensed Consolidated Balance Sheets - USD ($) $ in Thousands | Jun. 30, 2023 | Dec. 31, 2022 |
|---|---|---|
| Current Assets: | ||
| Cash and cash equivalents | $ 222,935 | $ 214,172 |
| Restricted cash | 311,425 | 301,446 |
| Accounts receivable, net of allowance of $11,610 at June 30, 2023 and $11,862 at December 31, 2022 | 185,881 | 183,110 |
| Inventories | 156,446 | 129,379 |
| Prepaid and refundable taxes | 26,302 | 31,708 |
| Prepaid expenses and other current assets | 38,846 | 26,321 |
| Total Current Assets | 941,835 | 886,136 |
| Property, plant and equipment, net | 149,568 | 147,187 |
| Goodwill | 779,212 | 768,787 |
| Intangible assets, net | 357,420 | 368,559 |
| Operating lease assets | 34,169 | 35,830 |
| Investments | 21,726 | 16,266 |
| Deferred tax assets | 2,113 | 1,384 |
| Long-term derivative assets | 42,034 | 54,393 |
| Other assets | 13,478 | 16,231 |
| Total Assets | 2,341,555 | 2,294,773 |
| Current Liabilities: | ||
| Current debt obligations | 19,074 | 23,434 |
| Accounts payable | 78,212 | 74,310 |
| Accrued liabilities and other | 82,038 | 81,481 |
| Current litigation provision liability | 22,352 | 29,481 |
| Taxes payable | 19,842 | 16,505 |
| Accrued employee compensation and related benefits | 66,646 | 72,187 |
| Total Current Liabilities | 288,164 | 297,398 |
| Long-term debt obligations | 567,951 | 518,067 |
| Contingent consideration | 92,626 | 85,292 |
| Deferred tax liabilities | 8,924 | 8,516 |
| Long-term operating lease liabilities | 27,229 | 29,548 |
| Long-term employee compensation and related benefits | 16,720 | 16,804 |
| Long-term derivative liabilities | 53,705 | 85,675 |
| Other long-term liabilities | 45,628 | 45,849 |
| Total Liabilities | 1,100,947 | 1,087,149 |
| Commitments and contingencies (Note 7) | ||
| Stockholders’ Equity: | ||
| Ordinary Shares, £1.00 par value: unlimited shares authorized; 53,903,564 shares issued and 53,830,387 shares outstanding at June 30, 2023; 53,851,979 shares issued and 53,564,664 shares outstanding at December 31, 2022 | 82,441 | 82,424 |
| Additional paid-in capital | 2,169,346 | 2,157,724 |
| Accumulated other comprehensive loss | (35,579) | (48,119) |
| Accumulated deficit | (975,505) | (984,030) |
| Treasury stock at cost, 73,177 ordinary shares at June 30, 2023; 287,315 ordinary shares at December 31, 2022 | (95) | (375) |
| Total Stockholders’ Equity | 1,240,608 | 1,207,624 |
| Total Liabilities and Stockholders’ Equity | $ 2,341,555 | $ 2,294,773 |
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. It operates through three segments: Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products. The Neuromodulation segment designs, develops, and markets VNS Therapy System, an implantable device that delivers vagus nerve stimulation (VNS) therapy for the treatment of drug-resistant epilepsy, difficult-to-treat depression, and obstructive sleep apnea. It is also involved in the development and clinical testing of the VITARIA System for treating heart failure through VNS. The Advanced Circulatory Support segment develops, produces, and sells temporary life support products, such as cardiopulmonary and respiratory support solutions. The company serves perfusionists, neurologists, neurosurgeons, and other physicians, as well as hospitals, other medical institutions, and healthcare providers. It sells its products through direct sales representatives and independent distributors. The company has a research collaboration with Verily to capture clinical biomarkers of depression. LivaNova PLC was founded in 1987 and is headquartered in London, the United Kingdom.